Chembio signs agreement with CDC contractor to develop a multiplex point-of-care test
Chembio announced it has entered into a follow-on, milestone-based development agreement with a private contracting organization acting on behalf of the CDC, for a multiplex POC influenza immunity test utilizing Chembio's patented Dual Path Platform (DPP®) technology. November 24, 2014